APA (7th ed.) Citation

Kwiatkowski, J., Walters, M. C., Hongeng, S., Yannaki, E., Kulozik, A., Kunz, J., . . . Thompson, A. A. (2024). Betibeglogene autotemcel gene therapy in patients with transfusion-dependent, severe genotype β-thalassaemia (HGB-212): A non-randomised, multicentre, single-arm, open-label, single-dose, phase 3 trial. The lancet, 404(10468), . https://doi.org/10.1016/S0140-6736(24)01884-1

Chicago Style (17th ed.) Citation

Kwiatkowski, Janet, et al. "Betibeglogene Autotemcel Gene Therapy in Patients with Transfusion-dependent, Severe Genotype β-thalassaemia (HGB-212): A Non-randomised, Multicentre, Single-arm, Open-label, Single-dose, Phase 3 Trial." The Lancet 404, no. 10468 (2024). https://doi.org/10.1016/S0140-6736(24)01884-1.

MLA (9th ed.) Citation

Kwiatkowski, Janet, et al. "Betibeglogene Autotemcel Gene Therapy in Patients with Transfusion-dependent, Severe Genotype β-thalassaemia (HGB-212): A Non-randomised, Multicentre, Single-arm, Open-label, Single-dose, Phase 3 Trial." The Lancet, vol. 404, no. 10468, 2024, https://doi.org/10.1016/S0140-6736(24)01884-1.